Literature DB >> 12433823

Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes.

Miki Nakajima1, Eriko Tanaka, Jun-Tack Kwon, Tsuyoshi Yokoi.   

Abstract

The nicotine and cotinine N-glucuronidations in human liver microsomes were characterized. The Eadie-Hofstee plots of nicotine N-glucuronidation in human liver microsomes were clearly biphasic, indicating the involvement of multiple enzymes. The apparent K(m) and V(max) values were 33.1 +/- 28.1 micro M and 60.0 +/- 21.0 pmol/min/mg and 284.7 +/- 122.0 micro M and 124.0 +/- 44.0 pmol/min/mg for the high- and low-affinity components, respectively, in human liver microsomes (n = 4). However, the Eadie-Hofstee plots of cotinine N-glucuronidation in human liver microsomes were monophasic (apparent K(m) = 1.9 +/- 0.3 mM, V(max) = 655.6 +/- 312.3 pmol/min/mg). The nicotine and cotinine N-glucuronidations in the recombinant human UDP-glucuronosyltransferases (UGTs) (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15) expressed in baculovirus-infected insect cells or human B-lymphoblastoid cells that are commercially available were determined. However, no recombinant UGT isoforms showed detectable nicotine and cotinine N-glucuronides (the concentrations of nicotine and cotinine were 0.5 and 2 mM, respectively). Nicotine and cotinine N-glucuronidations in pooled human liver microsomes were competitively inhibited by bilirubin as a substrate for UGT1A1 (K(i) = 3.9 and 3.3 micro M), imipramine as a substrate for UGT1A4 (K(i) = 6.1 and 2.7 micro M), and propofol as a substrate for UGT1A9 (K(i) = 6.0 and 12.0 micro M). The nicotine N-glucuronidation (50 micro M nicotine) in 14 human liver microsomes was significantly (r = 0.950, P < 0.0001) correlated with the cotinine N-glucuronidation (0.2 mM cotinine), indicating that the same isoform(s) is involved in both glucuronidations. Furthermore, weak correlations between imipramine N-glucuronidation and nicotine N-glucuronidation (r = 0.425) or cotinine N-glucuronidation (r = 0.517) were observed. In conclusion, the involvement of UGT1A1 and UGT1A9 as well as UGT1A4 in nicotine and cotinine N-glucuronidations in human liver microsomes was suggested, although the contributions of each UGT isoform could not be determined conclusively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433823     DOI: 10.1124/dmd.30.12.1484

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

Review 1.  Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.

Authors:  G Sharma; S Vijayaraghavan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

2.  UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.

Authors:  Catherine A Wassenaar; David V Conti; Soma Das; Peixian Chen; Edwin H Cook; Mark J Ratain; Neal L Benowitz; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-02       Impact factor: 4.254

3.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

Review 4.  Tailoring nicotine replacement therapy: rationale and potential approaches.

Authors:  Jennifer B McClure; Gary E Swan
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways.

Authors:  Taraneh Taghavi; Christopher A Arger; Sarah H Heil; Stephen T Higgins; Rachel F Tyndale
Journal:  J Pharmacol Exp Ther       Date:  2017-11-20       Impact factor: 4.030

Review 6.  Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism.

Authors:  Yadira X Perez-Paramo; Philip Lazarus
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-12-29       Impact factor: 4.481

Review 7.  Harmful effects of nicotine.

Authors:  Aseem Mishra; Pankaj Chaturvedi; Sourav Datta; Snita Sinukumar; Poonam Joshi; Apurva Garg
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

Review 8.  Variation in CYP2A6 Activity and Personalized Medicine.

Authors:  Julie-Anne Tanner; Rachel F Tyndale
Journal:  J Pers Med       Date:  2017-12-01

9.  Effects of Genetic Variants in the Nicotine Metabolism Pathway on Smoking Cessation.

Authors:  Huijie Li; Qiang Wang; Suyun Li; Chongqi Jia
Journal:  Genet Res (Camb)       Date:  2022-09-28       Impact factor: 1.375

10.  Genetic variants in CYP2A6 and UGT1A9 genes associated with urinary nicotine metabolites in young Mexican smokers.

Authors:  Gissela Borrego-Soto; Yadira X Perez-Paramo; Gang Chen; Sandra K Santuario-Facio; Jesus Santos-Guzman; Rodolfo Posadas-Valay; Fatima M Alvarado-Monroy; Isaias Balderas-Renteria; Ramses Medina-Gonzalez; Rocio Ortiz-Lopez; Philip Lazarus; Augusto Rojas-Martinez
Journal:  Pharmacogenomics J       Date:  2020-01-21       Impact factor: 3.550

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.